Non-Cancerous Blood Disease Market Outlook:
Non-Cancerous Blood Disease Market size was valued at USD 24.9 billion in 2024 and is projected to reach USD 47.8 billion by the end of 2034, rising at a CAGR of 7% during the forecast period 2025 to 2034. In 2025, the industry size of non-cancerous blood disease is estimated at USD 26.9 billion.
The global market is driven rapidly by an increase in the patient pool for non-cancerous blood disease. As per the WHO, over 1.9 billion people are affected by anemia, with iron deficiency being the major reason. In the U.S., the CDC states that nearly 3.4 million people experience anemia, and nearly 33,004 individuals are diagnosed with hemophilia. Moreover, according to the National Heart, Lung, and Blood Institute report, 100,005 people in America are affected by sickle cell disease. High levels of variability in the manufacture of active pharmaceutical ingredients (APIs) and the lack of adequate cold chain infrastructure in developing nations hinder the development and delivery of treatments for these people.
In the pricing point, as per the U.S. Bureau of Labor Statistics, the producer price index increased to 4.5% in 2023 for biological products such as hematology drugs. On the other hand, the consumer price index rose to 3.9% for prescription drugs, beating the inflation due to elevated prices of specialty biologics. The market has strong R&D investment, and NIH has allocated nearly USD 310 million to blood disease-related research, with major initiatives in newborn screening programs. China and India are significant exporters of raw materials and bulk medicinal substances, and the United States purchased more than USD 2.5 billion worth of blood-related medications and biologics in 2023. The market remains modest in export volumes as most domestic production is marked for internal healthcare consumption.
